Search results for: “ALXN”
-
Alexion Pharmaceuticals Inc Valuation – February 2019 $ALXN
Alexion Pharmaceuticals, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios.
-
Alexion Pharmaceuticals Inc Valuation – April 2018 $ALXN
Alexion Pharmaceuticals, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios.
-
Alexion Pharmaceuticals Inc Valuation – December 2016 $ALXN
Alexion Pharmaceuticals, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years, the poor dividend history, and the high PEmg and PB ratios.
-
Alexion Pharmaceuticals Inc. Analysis – August 2015 Update $ALXN
Alexion Pharmaceuticals Inc. is not suitable for the more conservative Defensive Investor or the Enterprising Investor. The Defensive Investor is concerned with the insufficient earnings growth or stability over the last ten years, the lack of dividends, and the high PEmg and PB ratios.
-
Alexion Pharmaceuticals Quarterly Valuation – May 2015 $ALXN
Alexion Pharmaceuticals is suitable for the Enterprising Investor but not for the Defensive Investor. The Defensive Investor is concerned by the lack of dividends, insufficient earnings stability or growth over the last ten years, and the high PEmg and PB ratios, while the Enterprising Investor is only concerned by the lack of dividends.
-
Alexion Pharmaceuticals Inc. Quarterly Valuation – January 2015 $ALXN
Alexion Pharmaceuticals Inc. is suitable for the Enterprising Investor but not for the Defensive Investor. The Defensive Investor is concerned by the insufficient earnings growth or stability over the last ten years, the lack of dividends and the high PEmg and PB ratios.
-
Alexion Pharmaceuticals Quarterly Stock Valuation – October 2014 $ALXN
Alexion Pharmaceuticals qualifies for the Enterprising Investor but not the Defensive Investor. The Defensive Investor has numerous concerns including the lack of earnings stability or growth over the last ten years, the lack of dividend payments and the high PEmg and PB ratios.
-
Johnson & Johnson Valuation – April 2019 #JNJ
Johnson & Johnson does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.
-
Bristol-Myers Squibb Co Valuation – April 2019 #BMY
Bristol-Myers Squibb Co is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PB ratio.
-
Biogen Inc Valuation – March 2019 #BIIB
Biogen Inc qualifies for both the Defensive Investor and the Enterprising Investor. The Defensive Investor is only initially concerned with the poor dividend history.